Exchanges: NASDAQ | NYSE | XLON | AMS | ADS | TSE | BRU

Financial News Feed

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 21) Array Biopharma Inc (NASDAQ: ARRY ) (announced positive late-stage results for its colorectal cancer combo drug) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 21) Adamis Pharmaceuticals Corp (NASDAQ: ADMP )(announced a patent litigation against it for its naloxone injection product candidate that is currently under regulatory review) BioCryst Pharmaceuticals, Inc (NASDAQ: BCRX )( reacted to late-stage study data for its hereditary angioedema prevention candidate) Cancer Genetics Inc (NASDAQ: CGI ) (reacted to its first-quarter results) Collegium Pharmaceutical Inc (NASDAQ: COLL ) Hookipa Pharma Inc (NASDAQ: HOOK ) (reacted to its first-quarter results) Ocular Therapeutix Inc (NASDAQ: OCUL ) ( reported negative Phase 3 readout for glaucoma treatment candidate) Theravance Biopharma Inc (NASDAQ: TBPH ) (reported Phase 1b data of its gut-selective pan-Janus kinase inhibitor TD-1473 at the Digestive Disease Week 2019) Trillium Therapeutics Inc (NASDAQ: TRIL ) Stock In Focus Tocagen's Brian Cancer Gene Therapy Trials Continue With Modification Tocagen Inc (NASDAQ: TOCA ) announced the Phase 3 trial evaluating its Toca 511 and Toca FC gene therapies in patients with recurrent high grade glioma continues without modification.

Read more

ZEAL earnings call for the period ending March 31, 2019.

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 30) VolitionRX Ltd (NYSE: VNRX ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE ) Down In The Dumps (Biotech stocks hitting 52-week lows on April 30) Acorda Therapeutics Inc (NASDAQ: ACOR ) Gamida Cell Ltd (NASDAQ: GMDA ) KemPharm Inc (NASDAQ: KMPH ) Meridian Bioscience, Inc. (NASDAQ: VIVO )(announced an agreement to acquire the business of GenePOC, a Canadian provider of molecular diagnostic instruments and assays) Outlook Therapeutics Inc (NASDAQ: OTLK ) Unum Therapeutics Inc (NASDAQ: UMRX ) Stock In Focus FDA Hands Out Complete Response Letter For Nabriva's Urinary Tract Infection Drug Nabriva Therapeutics PLC – ADR (NASDAQ: NBRV ) received a complete response letter, or CRL, from the FDA for its NDA for Contepo, chemically fosfomycin, injection for treating complicated urinary tract infections, including acute pyelonephritis.

Read more

Zealand Pharma A/S (ZEAL) has appointed Emmanuel Dulac as Chief Executive Officer, effective April 22, 2019. Most recently, Emmanuel has been the Chief Com

Read more

Fine tuning their focus in on Zealand Pharma A/S (:ZEAL) stock, investors are taking a closer look at the equity in recent weeks. Most recently the shares moved 1.43% landing at a price of $18.38. Sto

Read more

We are comparing Zealand Pharma A/S (NASDAQ:ZEAL) and Allakos Inc. (NASDAQ:ALLK) on their dividends, analyst recommendations, profitability, institutional

Read more

Stock market investors might be taking note of recent trends. Many investors will be digging deep into the numbers to try and spot potential breakouts. Following the numbers for Zealand Pharma A/S (:Z

Read more

Taking a look at the current quarter EPS consensus estimate for Zealand Pharma A/S (:ZEAL), we can see that the number is standing at -0.18. This estimate is comprised of 3 contributing analysts polle

Read more

Since Zealand Pharma A/S (NASDAQ:ZEAL) and Tiziana Life Sciences PLC (NASDAQ:TLSA) are part of the Biotechnology industry, they are influenced by contrast. The

Read more

The Earnings to Price yield of Zealand Pharma A/S (CPSE:ZEAL) is 0.154853. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most

Read more

Both Zealand Pharma A/S (NASDAQ:ZEAL) and Achieve Life Sciences Inc. (NASDAQ:ACHV) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, analyst recommenda

Read more

Both Zealand Pharma A/S (NASDAQ:ZEAL) and CytRx Corporation (NASDAQ:CYTR) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to institution

Read more

Investors tracking shares of Zealand Pharma A/S (:ZEAL) may be closely following analyst price target estimates. Reviewing company shares, we can see that the current average target price is 28.67. Ke

Read more

We will be comparing the differences between Cellular Biomedicine Group Inc. (NASDAQ:CBMG) and Zealand Pharma A/S (NASDAQ:ZEAL) as far as dividends, analyst recommendations, profitability, risk, insti

Read more

Zealand Pharma A/S (NASDAQ:ZEAL) and Intrexon Corporation (NASDAQ:XON) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as a

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank